Alivio Technology for Treating Inflammatory Diseases via Targeted Disease Immunomodulation Published in Nature Communications
Alivio Therapeutics, an affiliate of PureTech Health (PRTC.L), is pioneering targeted disease immunomodulation as a novel strategy to treat a range of chronic and acute inflammatory disorders. Targeted disease immunomodulation involves tuning the immune system exclusively at the site of disease in the body, with minimal impact on the rest of the immune system. This long sought-after approach has potential to treat a range of chronic and acute inflammatory disorders including ones that would otherwise be difficult to treat. Alivio’s proprietary Inflammation-Targeted Technology, based on the research of Dr. Karp and Dr. Robert Langer, David H. Koch Institute Professor at MIT, is the first technology to reproducibly show the ability to target immunomodulatory compounds to inflamed tissue, which can lead to dramatic improvements in treatment efficacy with major reductions in systemic effects. The platform has been validated in multiple labs and in eight different animal models of inflammation where the inflammation occurred in different parts of the body (e.g., the GI system, the bladder, joints, skin, etc.). The technology could potentially be used with a variety of medications (e.g., small molecules, peptides, proteins and nucleic acids) to address the dozens of conditions where inflammation is a central part of the underlying disease pathology, but where targeted and effective treatment options are lacking.
Alivio is developing its proprietary technology in collaboration with several of the world’s leading experts in biomaterials and immunology. Expert advisors include: Jeff Karp, PhD, Professor of Medicine at Brigham & Women’s Hospital and Alivio co-founder; Robert Langer, ScD, Co-Alivio Founder and Non-Executive Director at PureTech Health and David H. Koch Institute Professor at MIT; Michael B. Brenner, MD, Chief of the Division of Rheumatology, Immunology and Allergy at BWH; Ulrich H. von Andrian, MD, PhD, Mallinckrodt Professor of Immunopathology at Harvard Medical School; and Ralph Weissleder, MD, PhD, Director of the Center for Systems Biology at Massachusetts General Hospital.
Forward Looking Statement
This press release contains statements that are or may be forward-looking statements, including statements that relate to PureTech’s future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither PureTech Health nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Alivio Therapeutics